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For the purpose of developing a transglutaminase 
inhibitor which  could be effective in physiological and 
pharmacological studies, a series of phenylthiourea de- 
rivatives of a,o-diaminoalkanes were designed, syn- 
thesized, and evaluated kinetically as inhibitors of 
transglutaminases. A homologous series of compounds 
of the  structure phenylthiourea-(CHz),-NH2, where n 
= 2, 3, 4, 5,  and 6, were tested for the inhibition of 
both guinea pig liver transglutaminase-catalyzed 
amine incorporation into various glutamine-contain- 
ing substrates and plasma transglutaminase (factor 
XII1a)-catalyzed amine incorporation into  fibrin and 
fibrin cross-linking. It was found that  the inhibitory 
activity of the compounds increases with increasing 
number of methylene groups in the side chain up to a 
maximum of n = 5. A further increase in the length of 
the methylene side chain to n = 6 results in decreased 
activity. The Ki value (4.9 x lo-’ M) of 1-(5-sminopen- 
tyl)-3-phenylthiourea (PPTU) (n = 5)  for the inhibition 
of guinea pig transglutaminase-catalyzed amine incor- 
poration into  the B chain of oxidized insulin is in close 
agreement to its K,(app) value (7.1 X M) obtained 
using 14C-lybeled PPTU. PPTU was also found to be a 
potent inhibitor of plasma transglutaminase-catalyzed 
fibrin cross-linking. The finding that  the specificity of 
the alkylamines for inhibition is correlated with the 
length of their methyl side chains is compatible with 
those reported  for aliphatic amines and monodansyl- 
cadaverine analogues (where dansyl is 5-dimethyla- 
minonaphthalene-1-sulfonyl). The phenylthiourea de- 
rivatives, however, are far less toxic in mice than 
monodansylcadaverine as indicated by their LDEo val- 
ues: PPTU, 400 +. 26 mg/kg; and monodansylcadav- 
erine, 160 2 20 mglkg. 
Transglutaminases are Ca2+-dependent enzymes that cata- 
lyze the post-translational modification of proteins through 
exchange of primary amines for ammonia at the y-carbox- 
amide group of peptide-bound glutamine residues. These en- 
zymes are widely distributed in body fluids and tissues (for 
review, see Refs.  1-3) and  are  thought to play  a  role in cell 
activation and differentiation (4-7). A number of potential 
transglutaminase inhibitors have  been  developed during the 
past decade (8-11). Among the transglutaminase inhibitors 
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developed,  monodansylcadaverine (MDCl) analogues  were 
shown to be among the most  effective inhibitors of the  trans- 
glutaminase-catalyzed amine corporation into various gluta- 
mine-containing substrates and also in  the cross-link forma- 
tion between polypeptide chains in in vitro assay (8, 11). 
However, MDC was also shown to inhibit a number of other 
enzymes, e.g. 17-ketosteroid reductase (12), phosphatidylcho- 
line synthetase (13), as well as  the calmodulin activation of 
cyclic  nucleotide phosphodiesterase (14) and cell attachment 
(14). In  an effort to develop an inhibitor that is specific  for 
transglutaminases in cellular systems, we have prepared a 
number of phenylthiourea derivatives of a,@-diaminoalkanes 
and examined these as inhibitors of tissue and plasma trans- 
glutaminases. Preliminary studies showed that 1-(5-amino- 
pentyl)-3-phenylthiourea (PPTU), at Ki levels, caused no 
adverse  effect on several cellular  processes? This report pre- 
sents studies of the kinetic properties of phenylthiourea 
(PTU) derivatives of a,w-diaminoalkanes as inhibitors of the 
liver transglutaminase-catalyzed methylamine incorporation 
into various glutamine substrates and of the plasma transglu- 
taminase-catalyzed fibrin cross-linking. 
EXPERIMENTAL PROCEDURES3 
Materials-Guinea pig liver transglutaminase was prepared ac- 
cording to a published procedure (15). The enzyme exhibited 95 -C 
5% of the reported specific activity when assayed by hydroxamate 
formation with the substrate benzyloxycarbonyl-L-glutaminylglycine 
(Z-Gln-Gly) (15). An extinction coefficient of E!&,,, = 15.8 and a 
molecular weight of 80,000 were used to determine enzyme concen- 
tration (16). Human blood coagulation factor XI11 was isolated from 
95% clottable fibrinogen prepared from fresh ACD plasma (17,  18). 
Plasma factor XIIIa (plasma transglutaminase) formed from the 
zymogen upon activation with thrombin (18) showed 95% of the 
reported specific activity when assayed by [l4C1methylamine uptake 
by the acetylated B chain of oxidized insulin (18). An extinction 
coefficient E&&,,,, = 13.8  (19) and a molecular weight of  320,000 were 
used to determine zymogen concentration. [‘4C]Methylamine (102 
mCi/mmol) was purchased from New England Nuclear and was used 
without further purification. Z-Gln-Gly was a gift from Dr. J. E. Folk, 
National Institutes of Health, Bethesda, MD. The acetylated B chain 
The abbreviations used are: MDC, monodansykadaverine (where 
dansyl is 5-dimethylaminonaphthalene-1-sulfonyl); PPTU, 1-(5-ami- 
nopentyl)-3-phenylthiourea; PTU, phenylthiourea; EPTU, ethylam- 
inophenylthiourea; Z-Gln-Gly, benzyloxycarbonyl-L-glutaminylgly- 
cine. ‘ K. N. Lee, L. Fesus, S. T. Yancey, J. E. Girard, and S. I. Chung, 
manuscript in preparation. 
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of oxidized insulin was prepared as outlined previously (18). The 
concentrations of B chain of insulin stock solution were determined 
from amino acid analysis. Human thrombin was a gift from Dr. 
Genesio Murano, Bureau of Biologics, Food and Drug Administra- 
tion,  Bethesda, MD. Monodansylcadaverine hydrochloride was from 
Sigma. Methods for the synthesis of the  PTU derivatives of the 01,o- 
diaminoalkanes and [14C]PPTU and analytical data are presented in 
the Miniprint Supplement. 
Methods-Kinetic studies were carried out  at 37 "c in 0.1 M Tris 
acetate buffer (pH 7.5) containing 0.1 mM EDTA, 20 mM CaC12, and 
30 mM  NaC1. Apparent Michaelis constants for PPTU were measured 
for both guinea pig liver and plasma transglutaminase systems. For 
the liver enzyme, 0.02-0.10 mM [14C]PPTU was used with 0.2 mM B 
chain of oxidized insulin and 0.2-2.0 mM [14C]PPTU was used with 
4.0 mM Z-Gln-Gly. For the plasma enzyme, 0.01 mM fibrinogen, 2 
NIH  units of thrombin, 1 mM dithiothreitol, and 0.2-2.0 mM ["C] 
PPTU were used. Measurement of ['4C]PPTU incorporation into 
fibrin and  into  the B chain of oxidized insulin was made by  trichlo- 
roacetic acid precipitation of the proteins as described for factor 
XIIIa assay (18). The  rate of incorporation of [14C]PPTU into Z-Gln- 
Gly  was measured by thin layer chromatography on polyamide sheets 
(20). Measurement of incorporation of ['4C]methylamine into Z-Gln- 
Gly was made by a method using DEAE-cellulose paper strips (21). 
Inhibition  studies of liver transglutaminase-catalyzed methylamine 
incorporation into  the B chain of oxidized insulin and into Z-Gln- 
Gly  were performed in 100 pl  of reaction mixtures containing 0.1 M 
Tris acetate (pH 7.5), 0.1 mM EDTA, 20 mM CaCl,, 0.15 mg/ml 
enzyme, 0.37-2.0 mM [14C]methylamine, 0.1 mM B chain of oxidized 
insulin or 1.0 mM Z-Gln-Gly , and  up to 1 mM inhibitors. Inhibition 
studies of plasma transglutaminase-catalyzed reactions were carried 
out in reaction mixtures of 100 pl composed of 0.1 M Tris acetate 
buffer (pH 7.5), 0.1 mM EDTA, 1 mM dithiothreitol, 20 mM CaC12, 
0.01 mg/ml enzyme, 1.0-5.0 mM ["Clmethylamine, 0.01 mM fibrino- 
gen, 2 units of thrombin, and  up  to 1 mM inhibitors. Inhibition of 
fibrin clot stabilization was studied in 0.01 M Tris acetate buffer 
containing 2 mM  CaC12, 0.15 M NaC1, and 5 mM dithiothreitol at 
various inhibitor concentrations. The concentrations of fibrinogen 
and plasma transglutaminase were 2.5 and 0.015  mg/ml, respectively. 
Clot formation was initiated by the addition of 1 unit of thrombin. 
The clot was washed three times with cold 0.01 M Tris acetate buffer 
containing 2 mM EDTA and 0.15 M NaC1. The washed clot was placed 
in 6 M urea, and  the soluble protein was estimated by the method of 
Bradford (22). All kinetic studies were carried out under conditions 
where no more than 10% of the substrate at  the lowest concentration 
was consumed within the reaction periods. Reciprocal velocities were 
plotted  against the reciprocals of substrate concentration. The  data 
was fitted  to  the Michaelis-Menten equation (Equation 1) where the 
terms have their usual meaning: 
VA 
K,,, i- A' 
"=- 
All fits were performed by means of an interactive curve-fitting 
program, MLAE3, developed at  the National Institutes of Health and 
run on a DEC-10 computer (23). Data for linear competitive inhibi- 
tion were fitted to Equation 2 as follows. 
VA 
U =  
K,  (1 + Z/KJ + A 
Inhibitory activity of fibrin clot stabilization is expressed as per cent 
solubility in 6 M urea. Per  cent solubility was estimated from the 
fraction (Su - Su,I)/(Su,Ca - Su,I) where Su represents soluble 
proteins  in 6 M urea, su,Z represents soluble proteins  in 6 M urea  in 
the presence of inhibitor, and Su,Ca represents soluble protein in 6 
M urea in  the presence of Ca". The comparison of the inhibitory 
activity of each inhibitor is expressed as  that relative to  the inhibitor 
activity of PPTU.  PPTU caused a 50% inhibition of clot solubiliza- 
tion at  1 mM. 
Lethal dose effects of PPTU,  EPTU,  and MDC were measured in 
mice by intraperitoneal  administration of the inhibitors dissolved in 
sterile saline solution. A group of 10 mice  were utilized for each dose 
level of the compound, and survival rates were estimated from the 
percentage of animals that survived 7 days post-administration. A 
full tabulation of kinetic and inhibitor constants are presented in the 
Miniprint Supplement. 
RESULTS 
The liver transglutaminase is one of the most extensively 
studied transglutaminases with regard to  its substrate speci- 
ficity, structural properties, and cellular regulation (18, 24, 
25). Liver transglutaminase has been shown to have much 
broader substrate specificity than other transglutaminases 
(18,24). We selected two different glutamine-containing sub- 
strates for inhibitor studies: one, Z-Gln-Gly , is a simple, very 
small substrate  for liver transglutaminase, whereas the other, 
the B chain of oxidized insulin, is a more complex peptide 
that contains  a single glutamine residue and  that also serves 
as a substrate for both liver transglutaminase and factor 
XIIIa. The mode of inhibition by PTU derivatives of a,w- 
diaminoalkanes was examined by kinetic analysis. A double 
reciprocal plot of reaction velocities against methylamine 
concentration  in the presence and absence of PPTU is shown 
in Fig. 1. Saturating levels of the oxidized B chain of insulin 
were used as the glutamine substrate. The results show a 
typical competitive inhibition profile where only the slope 
(Ka/V)(l + I/Ki) is affected, without effect on the intercept. 
When the slopes from the double reciprocal plot were plotted 
against inhibitor concentrations, a linear fit was obtained 
(Fig. 1, inset), indicative of linear competitive inhibition as 
represented in Equation 2. The inhibition constants for the 
various chain length arylamines obtained using 2-Gln-Gly 
and  the oxidized B chain of insulin were compared as shown 
in Fig. 2; the arylamine with the pentamethylene chain be- 
tween the terminal amino group and  the  PTU group showed 
the greatest inhibitory activity, while that with the ethylene 
chain showed almost no activity. The arylamine with the 
hexamethylamine side chain showed slightly less inhibitor 
activity than  that with the pentamethylamine group. A similar 
pattern of inhibitor specificity between different alkylamine 
side chains of PTU was observed using the two glutamine 
substrates. However, the Ki value for each of the inhibitors 
obtained with the use of Z-Gln-Gly  was significantly higher 
than  that of the same inhibitor obtained with the oxidized B 
chain of insulin. 
Plasma  transglutaminase (factor XIIIa)  present in plasma 
1/CH2NH2 ImM) 
FIG. 1. Lineweaver-Burk  plots for guinea  pig liver trans- 
glutaminase-catalyzedCH3NH2 incorporation  into  the B chain 
of oxidized  insulin  in  the  presence (0) and  absence (A) of 0.1 
mM PPTU. Velocity is given in nanomoles of CH,NH2 incorporated 
per min/nmol of enzyme. Each  point  represents the average of dupli- 
cate determinations. The inset shows a plot of the slope against the 
inhibitor concentrations. 
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FIG. 2. Correlation between the methylene (-CH2-), side 
chain length of alkylamine  derivatives of PTU  and  the KJ 
values obtained with these inhibitors  in guinea pig liver  trans- 
glutaminase-catalyzed CHsNHz incorporation  into the B chain 
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FIG. 3. Correlation between methylene (-CH2-). side chain 
length of alkylamine  derivatives of PTU  and  the KS values 
obtained with these inhibitors  in plasma transglutaminase- 
catalyzed CaNHZ incorporation  into fibrinogen. 
and platelets  is the most abundant form of transglutaminase, 
but  it  has a more limited substrate specificity. The dipeptide, 
Z-Gln-Gly , which has been used as  an effective substrate for 
liver transglutaminase,  is  a very poor substrate for plasma 
transglutaminase. In plasma, this enzyme catalyzes the  inter- 
chain cross-linking of fibrin through t-(7-glutamy1)lysine 
bond formation. For  these  inhibition studies, fibrin was used 
as a glutamine substrate. Fig. 3 shows the -log Ki values 
obtained with the varying chain length arylamines. Again, the 
arylamine with the pentylamine side chain showed the highest 
inhibitor activity and that with the ethylamine side chain 
displayed practically no  inhibition. The arylamine with the 
hexylamine side chain was less inhibitory than  that with the 
pentylamine group. 
The inhibition of fibrin cross-linking was examined by clot 
solubility in  a chaotropic reagent (6 M urea). The fully cross- 
linked  fibrin polymer is the least soluble, whereas the non- 
cross-linked fibrin polymer is completely soluble in 6 M urea. 
In Fig. 4, the inhibitory effects of PPTU and  EPTU on fibrin 
clot solubility in 6 M urea  are shown. EPTU showed almost 
no effect, while in  the presence of PPTU,  there is a concen- 
tration-dependent increase of fibrin solubilization. A compar- 
ison of the relative inhibition of fibrin cross-linking by each 
inhibitor (Fig. 5) showed that  the arylamine with the pen- 
tylamine side chain was the most effective. Thus, with both 
the liver and the plasma transglutaminases, the structural 
requirement for alkylamine side chain  appears to be the same. 
5 60- 
u 
z a m 
LL 
0.5 1 .o 1.5 2.0 
INHIBITOR mM 
FIG. 4. Inhibition of fibrin clot stabilization by PPTU (0) 
and EPTU (A). 
6 
SIDE-CHAIN LENGTH ( - CH2- In 
FIG. 5. Correlation between methylene (-CHs-), side chain 
length of alkylamine derivatives of PTU and the relative 
inhibitory  activities  with these inhibitors  in plasma transglu- 
taminase-catalyzed fibrin clot stabilization (fibrin cross-link- 
ing). Relative activity was estimated from the per  cent solubility of 
fibrin clot in  the presence of 1.0 mM inhibitor divided by the  per cent 
solubility of fibrin clot in the presence of 1.0 mM PPTU. 
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TABLE I 
Kinetic constants obtained with P'CIPPTU and various glutamine 
substrates in the liver and plasma transglutaminases-catalyzed 
reaction 
Trans-  Glutamine Constants 
glutaminase  substrate" Kdauu) vb 
mM 
~~ ~ ~ 
min" 
Liver B chain of insulin 0.084 f 0.005  2.59 & 0.11 
Plasma  Fibrinogen 0.330 f 0.028 19.60 f 0.61 
a The concentrations  of  glutamine  substrates  used were as follows: 
B chain of insulin, 0.2 mM; Z-Gln-Gly,  4.0 mM; and  fibrinogen,  0.01 
mM. 
Values  for V are given in nanomoles of [14C]PPTU  incorporated 
per min/nmol of enzyme. 
Z-Gln-Gly  0.740 f 0.08 17.60 f 1.1 
I 
0 200 400 600 
Dose (mg/kg Body Wt.) 
FIG. 6. LDW of PPTU, EPTU, and MDC. The percentages  of 
istration  of  various  dose levels of PPTU (A), EPTU (U), and MDC 
survival  from the groups  of 10 mice  following  intraperitoneal  admin- 
(0) are shown. 
The inhibition expected by the arylamines probably is a 
result of their role as substrates. Thus,  the Michaelis constant 
obtained with the use of PPTU as second substrate should be 
in close agreement with its Ki value as an inhibitor. Table I 
shows the kinetic constants obtained from the direct incor- 
poration of [14C]PPTU into various glutamine substrates by 
both liver and plasma transglutaminase. The K,(app) values 
obtained are within the range of experimental error for the 
comparable Ki values  (see Tables 11-IV). 
In order to evaluate the physiological tolerance of PPTU, 
EPTU,  and MDC, various dose  levels of the inhibitors were 
administered to mice by intraperitoneal injection and the 
lethal dose  response was examined  over a 7-day  period. Those 
animals which were affected died within a 24-h period. As 
shown in Fig. 6, MDC is the most toxic (LD5~ = 160  mg/kg), 
whereas PPTU was tolerated at three times higher levels. 
EPTU showed  no lethal effect at these dose  levels. 
DISCUSSION 
A series of phenylthiourea derivatives of a,w-diaminoal- 
kanes were synthesized to be examined as possible inhibitors 
of factor XI11 and tissue transglutaminase-mediated reactions 
in pathogenesis (27). These derivatives were  designed to have 
three structural features: 1) a primary amino group which 
should compete with second substrate by means of nucleo- 
philic substitution at the acyl-enzyme intermediate during 
catalysis; 2) a hydrophobic phenyl group to enhance affinity 
of the inhibitor for subsites near the catalytic site of the 
enzyme and to promote better diffusion into cells; and 3) a 
thiourea group to increase solubility in physiological  media. 
The kinetic analysis of PPTU inhibition of methylamine 
incorporation into the B chain of oxidized insulin showed 
linear competitive inhibition as defined by Equation 2 (Fig. 
1). In order to evaluate and compare the inhibition constants 
presented here, separate experiments were done to measure 
the apparent K, value by direct incorporation of [14C]PPTU 
using the same glutamine substrate. Under these conditions, 
the K,,,(app) value obtained was equal to  the Ki values  for this 
amine, evidence that inhibition is, indeed, a consequence of 
the substrate property of the arylamine. For the various 
arylamines tested, greater specificity  is  reflected in  the higher 
-log Ki values presented in Figs. 2,3, and 5. Examination of 
the  data presented in these figures  reveals  some interesting 
features of the amine inhibitor specificity of the acyl-enzyme 
intermediates formed with liver and plasma enzymes. As the 
number of methylene groups between PTU and  the amino 
group is increased up to a certain number, progressively better 
inhibitor activity is  observed. The peak inhibitor activity is 
noted with the pentylamine side chain, and an increase in 
chain length of one methylene group caused a decline of 
inhibitor activity. The  PTU derivative of diaminopentane is 
a better inhibitor (2 orders of magnitude) than  the best of the 
aliphatic amines studied (26), suggesting that orientation of 
PPTU in the acyl-enzyme intermediate may involve addi- 
tional binding sites for the  PTU group. A similar suggestion 
has been  made  regarding the binding of monodansylcadaver- 
ine (11). The amino group in each of the inhibitors used  here 
would be  likely to have about the same pK,,  10.6 f 0.1. The 
€-amino group of a lysine residue in a peptide possesses 
approximately the same pK, (28, 29). It is interesting to 
examine the effectiveness of these inhibitors on the basis that 
only the non-ionized form of an amine acts as a second 
substrate (30, 31). If Michaelis constants can be expressed 
relative to  the effective concentration of unprotonated amine 
species existing at  the  pH of the experiments (pH 7.5) rather 
than on the basis of the total concentration of the amine 
substrate, K ,  for PPTU can be estimated as 6.7 X lo-', which 
indicates that  it is  indeed an excellent substrate. 
Preliminary studies2 on the uptake and distribution of  ['"C] 
PPTU showed rapid diffusion into Chinese hamster ovary 
cells. At concentrations near its Ki values, no inhibitory 
activity was  observed  on the calmodulin-dependent nucleotide 
phosphodiesterase, and no  effect on cell proliferation of 
Chinese hamster ovary and B16  melanoma  cells in vitro was 
observed. In  the animal experiment, PPTU was shown to be 
effective in retardation of  Lewis lung carcinoma cell metas- 
tasis in mice? These results suggest that the phenylthiourea 
derivative of pentylamine is an excellent transglutaminase 
inhibitor and may  be useful in  the study of transglutaminase 
function in cellular systems. 
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6 26.5 (C-a), 26.7  (C-h),  29.0  (C-e).  33.6  (Fd).  42.0  (C-E).  45.4  (C-f).  125.1 (Ca). 126.9 
(c-h).  129.9  (c-i),  136.8  (C-j), 181.0 (C-k).  Anel. Calcd  for CI3 RZ1 N3 S: C,  62.13; E. 
8.36; 1. 16.73.  Found: c. 62.06; 8 8.59; N. 16.46. 
Table I1 
Tranaglutaminase  catalyzed  Metbylamine  incorporation i to the B chain of 
Kinetic  Constants of PTU derivatives of Alkylamines  in  the  Liver 
oxidized I m l i n  
Inbibitor  constanta' 
K 
pm-im'j2-mz 0.99 t 0.06 0.24 2 0.01 3.09 2 0.04 
~ ." 
Pl'Ll-(C!32)3-NK2 0.22 2 0.02 0.23 t 0.02 3.04 2 0.05 
P'IlJ-(Caz)4-Wa2 0.0492  04 0.25 2 0.02 2.49 t 0.13 
Pl'U-(Ca~)~-NE~ 0.27 t 0.02 0.26 t 0.03 3.10 2 0.16 
Plonodan$Ycad&erine 0.025t 0.002 0.24 t 0.02 3.07 t 0.09 
The values  for  the eOnstmts were  obtained by fits  to  Equation 2. KI. 
methylamine; V. the  apparent maximum velocity of methylamine 
the  inhibitor  constant; K, the  apparent  Wichaelis  constant  for 
incorporation. 
enzyme. 
bl  Values  for  V  are  given n nmoles of CE AB incorporated/dnl-le of 
A.I.: no idlibition. 
3 2  
Development of Selective Inhibitors of Transglutaminuse 
Kinetic Constants of P'CU derivatives of Illk.llamims in the Liver 
Transglutadnase catalyzed Uethylamine Incorporation into  2-Gln-Gly 
Table I11 
Inhibitor Constant=/ 
I V  (min-1)
PT"a ) -NB N.I.* 
pro-(Ca2)2-NE2 9.17 _+ 0.8  
Pm-(CH2)3-NB2 2.54 t 0.2 
0.36 _+ 0.03 14.9 t. 0.8 
0.35 t 0.02 15.6 t 1.3 
~onodan&fcadverine 0.25 t 0.03 0.41 0.04  14.6 t 1.2 
1.08 t 0.08  0.39 t 0.03 15.9 t 1.4 
P T " 5 4 - N a 2  0.46 t 0.04 0.40 t 0.04  14.8 t 0.1 
Pm-(rn2)5-NE2 
Kinetic Constauts of PTO derivatives of Alkylamines in the Plasma Factor 
Table IV 




PTLI-(CE ) -NX N.I.* 
m-cmZ)3-mZ 
' O'' 1.25 t 0.12 
1.45 t 0 . 2  
18.65 t. 0.99 
1.14 t 0.11 
PllJ-tC&?-NE! 0.44 t 0.04 1.38 t 0.14 
17.56 t 0.46 
18.34 t 0.72 
PTU-(cE2)2-NG 
pTi-(nlLjD-mz 1.06 t 0.1 
Nonodanzyhadiverine 0.21 t. 0.01 1.32 * 0.10 1.30 t 0.12 19-09 t 0.18 19.01 f_ 0.16 
aJ The values for the constants vere obtained by fits to Equation 2 .  
Ki, the inhibitor constant; K. the apparent Michaelis constant for 
methylamine; V. the apparent merimurn velocity of methylamine 
incorporation. 
* N.I.: no  inhibition. 
The values for the constants vere obtained  by fits to Muation 2. 
Ki, the inhibitor consrant: K, the apparent Michaelis constant for 
methylamine; V, the apparent maximum velociry of methylamine 
incorporation. 
* N.I.: no inhibition. 
